💰 The investment supports scalable production. Samabriva’s automated bioproduction system will enhance efficiency.
🚀 The first phase will be operational by Q1 2025, aiming to transform the production landscape.
Introduction:
Samabriva, a France-based plant biotechnology company, has unveiled a new biomanufacturing facility in Liege, Belgium, taking a significant step towards advancing plant-based production methods for high-value natural molecules used in pharmaceuticals.
- The new facility spans 1,400 m² and represents a multi-million Euro investment aimed at large-scale production of biologically active molecules derived from plants.
- Samabriva specializes in an automated bioproduction system, enabling clients to produce various natural compounds and recombinant proteins.
- The facility will enhance efficiency through specialized bioreactors designed specifically for hairy root culture, thereby improving production output.
- Chairman Pascal Lizin highlighted the facility’s potential to offer cost-effective solutions by managing the entire value chain for international customers.
- Phase one of operations is expected to commence by the first quarter of 2025, marking a pivotal milestone for Samabriva in the field of biomanufacturing.
Conclusion:
The establishment of this biomanufacturing facility underscores Samabriva’s commitment to expanding the horizons of plant-based biotechnology, with implications for enhanced supply chain efficiency and the production of valuable pharmaceutical constituents. As the facility becomes operational, it is poised to attract interest from companies seeking sustainable production methods for high-value molecules.
